News | Stents Drug Eluting | May 31, 2018

Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial

BIO-RESORT one- to two-year landmark analysis shows significantly lower TLF and TLR rates for Orsiro compared to Resolute Integrity, with a favorable trend compared to Synergy

Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial

May 31, 2018 — Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials session at EuroPCR 2018, May 21-24 in Paris, France.

Results from this large-scale, three-arm trial with complex all-comers population treated with highly dissimilar contemporary drug-eluting stents (DES) confirmed the trend seen with the one-year data, supporting the use of ultrathin bioabsorbable polymer DES.

Data were presented by Dr. Marlies M. Kok, Thoraxcentrum Twente, MST, Enschede, the Netherlands and simultaneously published in EuroIntervention.

At the two-year follow-up in the BIO-RESORT trial (n=3,514), all three stents showed low target vessel failure (TVF) rates. Orsiro1 demonstrated a favorable trend without reaching statistical significance2 (Orsiro 6.6 percent, Synergy3 6.8 percent, Resolute Integrity4 8.3 percent).

The landmark analysis2 evaluating the incremental events between the first and second year of follow-up showed patients in the Orsiro arm with significantly lower rates of target lesion failure (TLF) in comparison to the permanent-polymer DES arm (respectively Orsiro 1.1 percent, Resolute Integrity 2.4 percent p=0.02) and numerically lower than in the biodegradable-polymer DES Synergy arm (Synergy 1.6 percent, Resolute Integrity 2.4 percent p=0.22). Furthermore, the landmark analysis demonstrated that Orsiro achieved the lowest rate of TLR beyond one year across all arms (respectively Orsiro 0.6 percent, Resolute Integrity 1.5 percent p=0.04; Synergy 0.9 percent, Resolute Integrity 1.5 percent p=0.18).

The investigators noted that “very thin-strut biodegradable polymers DES have flexible designs and refined coatings to promote re-endothelialization and reduce the risk of ischemic coronary events.” They also noted that “given those signals seen from the landmark analysis, the ultrathin 60 micron5 bioabsorbable polymer Orsiro DES might reduce the risk of repeat revascularization after the first year of follow-up.”

This data is in line with previously presented BIOFLOW-V6 results demonstrating significantly better outcomes for Orsiro compared to a permanent polymer DES (Xience7).

Read the February 2019 article FDA Clears Biotronik Orsiro Stent That Outperforms Xience

For more information: www.biotronik.com


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now